-
Product Insights
Net Present Value Model: Xinyue
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Xinyue Drug Details Inebilizumab-cdon (Uplizna, Xinyue)...
-
Product Insights
Net Present Value Model: AQP-4
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AQP-4 Drug Details AER-271 is under...
-
Product Insights
Net Present Value Model: AAV-AQP1
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AAV-AQP1 Drug Details AAV-AQP1 is under...
-
Product Insights
Net Present Value Model: Enspryng
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Enspryng Drug Details Satralizumab (Enspryng) is...
-
Product Insights
Net Present Value Model: Soliris
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Soliris Drug Details Eculizumab (Soliris) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AER-271
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AER-271 Drug Details AER-271 is under development for the treatment of stroke-related cerebral edema....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AAV-AQP1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AAV-AQP1 Drug Details AAV-AQP1 is under development for the treatment of xerostomia resulting from...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – inebilizumab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry inebilizumab Drug Details Inebilizumab-cdon (Uplizna, Xinyue) is a CD19-directed glyco-engineered humanized afucosylated IgG1 monoclonal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – eculizumab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry eculizumab Drug Details Eculizumab (Soliris) is a humanized monoclonal antibody directed against terminal complement...
-
Product Insights
Aquaporin 4 (Mercurial Insensitive Water Channel or WCH4 or AQP4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Aquaporin 4 (Mercurial Insensitive Water Channel or WCH4 or AQP4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Aquaporin 4 (Mercurial Insensitive Water Channel or WCH4 or AQP4) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics,...